

# George C Tsokos

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2197883/publications.pdf>

Version: 2024-02-01

527  
papers

27,279  
citations

8755

77  
h-index

15253

130  
g-index

569  
all docs

569  
docs citations

569  
times ranked

22956  
citing authors

#	ARTICLE	IF	CITATIONS
1	Systemic Lupus Erythematosus. <i>New England Journal of Medicine</i> , 2011, 365, 2110-2121.	13.9	2,265
2	Heat Shock Protein 70 kDa <i>Molecular Biology, Biochemistry, and Physiology.</i> , 1998, 80, 183-201.		1,010
3	New insights into the immunopathogenesis of systemic lupus erythematosus. <i>Nature Reviews Rheumatology</i> , 2016, 12, 716-730.	3.5	909
4	Expanded Double Negative T Cells in Patients with Systemic Lupus Erythematosus Produce IL-17 and Infiltrate the Kidneys. <i>Journal of Immunology</i> , 2008, 181, 8761-8766.	0.4	678
5	Pathogenesis of Human Systemic Lupus Erythematosus: A Cellular Perspective. <i>Trends in Molecular Medicine</i> , 2017, 23, 615-635.	3.5	328
6	Pathogenesis of human systemic lupus erythematosus: recent advances. <i>Trends in Molecular Medicine</i> , 2010, 16, 47-57.	3.5	311
7	Autoimmunity and organ damage in systemic lupus erythematosus. <i>Nature Immunology</i> , 2020, 21, 605-614.	7.0	294
8	The Role of IL-23/IL-17 Axis in Lupus Nephritis. <i>Journal of Immunology</i> , 2009, 183, 3160-3169.	0.4	268
9	Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study. <i>Lancet, The</i> , 2018, 392, 1330-1339.	6.3	244
10	T cells as therapeutic targets in SLE. <i>Nature Reviews Rheumatology</i> , 2010, 6, 317-325.	3.5	230
11	Regulatory T cells in the treatment of disease. <i>Nature Reviews Drug Discovery</i> , 2018, 17, 823-844.	21.5	224
12	Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 2014-2021.	0.5	200
13	Systemic lupus erythematosus serum IgG increases CREM binding to the IL-2 promoter and suppresses IL-2 production through CaMKIV. <i>Journal of Clinical Investigation</i> , 2005, 115, 996-1005.	3.9	199
14	Phosphatase PP2A is requisite for the function of regulatory T cells. <i>Nature Immunology</i> , 2016, 17, 556-564.	7.0	191
15	Molecular Basis of Deficient IL-2 Production in T Cells from Patients with Systemic Lupus Erythematosus. <i>Journal of Immunology</i> , 2001, 166, 4216-4222.	0.4	188
16	T cell signaling abnormalities contribute to aberrant immune cell function and autoimmunity. <i>Journal of Clinical Investigation</i> , 2015, 125, 2220-2227.	3.9	185
17	Glutathione peroxidase 4-regulated neutrophil ferroptosis induces systemic autoimmunity. <i>Nature Immunology</i> , 2021, 22, 1107-1117.	7.0	185
18	CaMK4-dependent activation of AKT/mTOR and CREM underlies autoimmunity-associated Th17 imbalance. <i>Journal of Clinical Investigation</i> , 2014, 124, 2234-2245.	3.9	185

#	ARTICLE	IF	CITATIONS
19	Cutting Edge: IL-23 Receptor Deficiency Prevents the Development of Lupus Nephritis in C57BL/6 Mice. <i>Journal of Immunology</i> , 2010, 184, 4605-4609.	0.4	175
20	T cell metabolism: new insights in systemic lupus erythematosus pathogenesis and therapy. <i>Nature Reviews Rheumatology</i> , 2020, 16, 100-112.	3.5	174
21	Microglia-dependent synapse loss in type I interferon-mediated lupus. <i>Nature</i> , 2017, 546, 539-543.	13.7	173
22	Alterations in Lipid Raft Composition and Dynamics Contribute to Abnormal T Cell Responses in Systemic Lupus Erythematosus. <i>Journal of Immunology</i> , 2004, 172, 7821-7831.	0.4	172
23	Mechanisms of Immune Complex-Mediated Neutrophil Recruitment and Tissue Injury. <i>Circulation</i> , 2009, 120, 2012-2024.	1.6	171
24	Aberrant T Cell Signaling and Subsets in Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , 2018, 9, 1088.	2.2	170
25	Phosphorylated ERM Is Responsible for Increased T Cell Polarization, Adhesion, and Migration in Patients with Systemic Lupus Erythematosus. <i>Journal of Immunology</i> , 2007, 178, 1938-1947.	0.4	169
26	Mice Deficient in Complement Receptors 1 and 2 Lack a Tissue Injury-Inducing Subset of the Natural Antibody Repertoire. <i>Journal of Immunology</i> , 2002, 169, 2126-2133.	0.4	165
27	Fc $\gamma$ receptor type I $\gamma$ chain replaces the deficient T cell receptor $\gamma$ chain in T cells of patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2001, 44, 1114-1121.	6.7	158
28	Abnormalities of T cell signaling in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2011, 13, 207.	1.6	157
29	Human TCR $\alpha\beta$ <sup>+</sup> CD4 <sup>+</sup> CD8 <sup>-</sup> T Cells Can Derive from CD8 <sup>+</sup> T Cells and Display an Inflammatory Effector Phenotype. <i>Journal of Immunology</i> , 2009, 183, 4675-4681.	0.4	154
30	Epigenetic mechanisms in systemic lupus erythematosus and other autoimmune diseases. <i>Trends in Molecular Medicine</i> , 2011, 17, 714-724.	3.5	154
31	Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection. <i>Journal of Clinical Investigation</i> , 2005, 115, 2444-2453.	3.9	153
32	T cells in Systemic Lupus Erythematosus. <i>Current Opinion in Immunology</i> , 2016, 43, 32-38.	2.4	150
33	Stat3 promotes IL-10 expression in lupus T cells through trans-activation and chromatin remodeling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 13457-13462.	3.3	148
34	Renal and Metabolic Complications of Undifferentiated and Lymphoblastic Lymphomas. <i>Medicine (United States)</i> , 1981, 60, 218-229.	0.4	143
35	Abnormal T cell signal transduction in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2002, 46, 1139-1154.	6.7	141
36	Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future. <i>Current Opinion in Rheumatology</i> , 2005, 17, 550-557.	2.0	136

#	ARTICLE	IF	CITATIONS
37	Protein phosphatase 2A is a negative regulator of IL-2 production in patients with systemic lupus erythematosus. <i>Journal of Clinical Investigation</i> , 2005, 115, 3193-3204.	3.9	134
38	Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice. <i>Arthritis and Rheumatism</i> , 2010, 62, 2086-2092.	6.7	125
39	cAMP-responsive Element Modulator (CREM) $\pm$ Protein Induces Interleukin 17A Expression and Mediates Epigenetic Alterations at the Interleukin-17A Gene Locus in Patients with Systemic Lupus Erythematosus. <i>Journal of Biological Chemistry</i> , 2011, 286, 43437-43446.	1.6	122
40	The IL-2 Defect in Systemic Lupus Erythematosus Disease Has an Expansive Effect on Host Immunity. <i>Journal of Biomedicine and Biotechnology</i> , 2010, 2010, 1-6.	3.0	120
41	The Dysregulation of Cytokine Networks in Systemic Lupus Erythematosus. <i>Journal of Interferon and Cytokine Research</i> , 2011, 31, 769-779.	0.5	120
42	Pathogenic Natural Antibodies Recognizing Annexin IV Are Required to Develop Intestinal Ischemia-Reperfusion Injury. <i>Journal of Immunology</i> , 2009, 182, 5363-5373.	0.4	116
43	An Autoimmunogenic and Proinflammatory Profile Defined by the Gut Microbiota of Patients With Untreated Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2021, 73, 232-243.	2.9	115
44	The FcR $\gamma$ 3 Subunit and Syk Kinase Replace the CD3 $\zeta$ -Chain and ZAP-70 Kinase in the TCR Signaling Complex of Human Effector CD4 T Cells. <i>Journal of Immunology</i> , 2003, 170, 4189-4195.	0.4	113
45	Human Complement Receptor Type 1/CD35 Is an Epstein-Barr Virus Receptor. <i>Cell Reports</i> , 2013, 3, 371-385.	2.9	113
46	Systemic lupus erythematosus serum IgG increases CREM binding to the IL-2 promoter and suppresses IL-2 production through CaMKIV. <i>Journal of Clinical Investigation</i> , 2005, 115, 996-1005.	3.9	109
47	Immune cell signaling defects in lupus: activation, anergy and death. <i>Trends in Immunology</i> , 1999, 20, 119-124.	7.5	108
48	T cells and autoimmune kidney disease. <i>Nature Reviews Nephrology</i> , 2017, 13, 329-343.	4.1	106
49	IL-2 Protects Lupus-Prone Mice from Multiple End-Organ Damage by Limiting CD4 $\sim$ CD8 $\hat{=}$ IL-17 $\hat{=}$ Producing T Cells. <i>Journal of Immunology</i> , 2014, 193, 2168-2177.	0.4	105
50	Rewiring the T-cell: signaling defects and novel prospects for the treatment of SLE. <i>Trends in Immunology</i> , 2003, 24, 259-263.	2.9	104
51	Reconstitution of deficient T cell receptor $\gamma$ chain restores T cell signaling and augments T cell receptor/CD3-induced interleukin-2 production in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2003, 48, 1948-1955.	6.7	103
52	Defective CD3-Mediated Cell Death in Activated T Cells from Patients with Systemic Lupus Erythematosus: Role of Decreased Intracellular TNF $\hat{=}$ . <i>Clinical Immunology and Immunopathology</i> , 1996, 81, 293-302.	2.1	102
53	The CD38/NAD/SIRTUIN1/EZH2 Axis Mitigates Cytotoxic CD8 $\hat{=}$ Cell Function and Identifies Patients with SLE Prone to Infections. <i>Cell Reports</i> , 2020, 30, 112-123.e4.	2.9	102
54	B cell $\hat{=}$ intrinsic deficiency of the Wiskott-Aldrich syndrome protein (WASp) causes severe abnormalities of the peripheral B-cell compartment in mice. <i>Blood</i> , 2012, 119, 2819-2828.	0.6	99

#	ARTICLE	IF	CITATIONS
55	Gene-function studies in systemic lupus erythematosus. <i>Nature Reviews Rheumatology</i> , 2013, 9, 476-484.	3.5	99
56	Differential Expression and Molecular Associations of Syk in Systemic Lupus Erythematosus T Cells. <i>Journal of Immunology</i> , 2008, 181, 8145-8152.	0.4	97
57	SLAM family receptors and the SLAM-associated protein (SAP) modulate T cell functions. <i>Seminars in Immunopathology</i> , 2010, 32, 157-171.	2.8	96
58	Cholera Toxin B Accelerates Disease Progression in Lupus-Prone Mice by Promoting Lipid Raft Aggregation. <i>Journal of Immunology</i> , 2008, 181, 4019-4026.	0.4	95
59	Induction of the <i>CTLA-4</i> Gene in Human Lymphocytes Is Dependent on NFAT Binding the Proximal Promoter. <i>Journal of Immunology</i> , 2007, 179, 3831-3840.	0.4	94
60	Antisense Cyclic Adenosine 5'-Monophosphate Response Element Modulator Up-Regulates IL-2 in T Cells from Patients with Systemic Lupus Erythematosus. <i>Journal of Immunology</i> , 2002, 169, 4147-4152.	0.4	93
61	cAMP response element modulator $\hat{\pm}$ controls <i>IL2</i> and <i>IL17A</i> expression during CD4 lineage commitment and subset distribution in lupus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 16606-16611.	3.3	92
62	How signaling and gene transcription aberrations dictate the systemic lupus erythematosus T cell phenotype. <i>Trends in Immunology</i> , 2008, 29, 110-115.	2.9	91
63	Calcium/Calmodulin-Dependent Protein Kinase IV Suppresses IL-2 Production and Regulatory T Cell Activity in Lupus. <i>Journal of Immunology</i> , 2012, 189, 3490-3496.	0.4	91
64	The Catalytic Subunit of Protein Phosphatase 2A (PP2Ac) Promotes DNA Hypomethylation by Suppressing the Phosphorylated Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase (ERK) Kinase (MEK)/Phosphorylated ERK/DNMT1 Protein Pathway in T-cells from Controls and Systemic Lupus Erythematosus Patients. <i>Journal of Biological Chemistry</i> , 2013, 288, 21936-21944.	1.6	91
65	Transcriptional regulation of IL-2 in health and autoimmunity. <i>Autoimmunity Reviews</i> , 2009, 8, 190-195.	2.5	89
66	T cells and IL-17 in lupus nephritis. <i>Clinical Immunology</i> , 2017, 185, 95-99.	1.4	89
67	Suppression of autoimmunity and organ pathology in lupus-prone mice upon inhibition of calcium/calmodulin-dependent protein kinase type IV. <i>Arthritis and Rheumatism</i> , 2011, 63, 523-529.	6.7	87
68	Complement Receptor 1 Is a Sialic Acid-Independent Erythrocyte Receptor of <i>Plasmodium falciparum</i> . <i>PLoS Pathogens</i> , 2010, 6, e1000968.	2.1	86
69	DNA methylation in systemic lupus erythematosus. <i>Epigenomics</i> , 2017, 9, 505-525.	1.0	86
70	Overexpression of HSP70 inhibits the phosphorylation of HSF1 by activating protein phosphatase and inhibiting protein kinase C activity. <i>FASEB Journal</i> , 1998, 12, 451-459.	0.2	84
71	Anti-Phospholipid Antibodies Restore Mesenteric Ischemia/Reperfusion-Induced Injury in Complement Receptor 2/Complement Receptor 1-Deficient Mice. <i>Journal of Immunology</i> , 2004, 173, 7055-7061.	0.4	84
72	Depletion of gut commensal bacteria attenuates intestinal ischemia/reperfusion injury. <i>American Journal of Physiology - Renal Physiology</i> , 2011, 301, G1020-G1030.	1.6	83

#	ARTICLE	IF	CITATIONS
73	Deletion of microRNA-155 reduces autoantibody responses and alleviates lupus-like disease in the Fas <sup>lpr</sup> mouse. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 20194-20199.	3.3	83
74	IL-23 Limits the Production of IL-2 and Promotes Autoimmunity in Lupus. Journal of Immunology, 2017, 199, 903-910.	0.4	83
75	Immunodeficiency and autoimmunity: lessons from systemic lupus erythematosus. Trends in Molecular Medicine, 2012, 18, 101-108.	3.5	82
76	IL-17 in Systemic Lupus Erythematosus. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-4.	3.0	81
77	cAMP-responsive Element Modulator (CREM) <sup>1</sup> ± Protein Signaling Mediates Epigenetic Remodeling of the Human Interleukin-2 Gene. Journal of Biological Chemistry, 2011, 286, 43429-43436.	1.6	81
78	Immune cells and cytokines in systemic lupus erythematosus: an update. Current Opinion in Rheumatology, 2005, 17, 518-522.	2.0	80
79	Increased expression of STAT3 in SLE T cells contributes to enhanced chemokine-mediated cell migration. Autoimmunity, 2007, 40, 1-8.	1.2	80
80	Interleukin-17-producing T cells in lupus. Current Opinion in Rheumatology, 2010, 22, 499-503.	2.0	80
81	CaMK4 compromises podocyte function in autoimmune and nonautoimmune kidney disease. Journal of Clinical Investigation, 2018, 128, 3445-3459.	3.9	80
82	Increased Levels of NF-ATc2 Differentially Regulate CD154 and IL-2 Genes in T Cells from Patients with Systemic Lupus Erythematosus. Journal of Immunology, 2007, 178, 1960-1966.	0.4	79
83	Transcriptional factor ICER promotes glutaminolysis and the generation of Th17 cells. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 2478-2483.	3.3	79
84	Pyruvate kinase M2 is requisite for Th1 and Th17 differentiation. JCI Insight, 2019, 4, .	2.3	79
85	Complement, natural antibodies, autoantibodies and tissue injury. Autoimmunity Reviews, 2006, 5, 89-92.	2.5	77
86	IL-17 producing CD4+ T cells mediate accelerated ischemia/reperfusion-induced injury in autoimmunity-prone mice. Clinical Immunology, 2009, 130, 313-321.	1.4	77
87	cAMP responsive element modulator: a critical regulator of cytokine production. Trends in Molecular Medicine, 2013, 19, 262-269.	3.5	77
88	Protein Phosphatase 2A Enables Expression of Interleukin 17 (IL-17) through Chromatin Remodeling. Journal of Biological Chemistry, 2013, 288, 26775-26784.	1.6	77
89	B Cells, Be Gone – B-Cell Depletion in the Treatment of Rheumatoid Arthritis. New England Journal of Medicine, 2004, 350, 2546-2548.	13.9	76
90	Expression of CD44 variant isoforms CD44v3 and CD44v6 is increased on T cells from patients with systemic lupus erythematosus and is correlated with disease activity. Arthritis and Rheumatism, 2010, 62, 1431-1437.	6.7	76

#	ARTICLE	IF	CITATIONS
91	Essential role for the prolyl isomerase Pin1 in Toll-like receptor signaling and type I interferon-mediated immunity. <i>Nature Immunology</i> , 2011, 12, 733-741.	7.0	76
92	Complement Inhibitor, Complement Receptor 1-Related Gene/Protein $\gamma$ -Ig Attenuates Intestinal Damage After the Onset of Mesenteric Ischemia/Reperfusion Injury in Mice. <i>Journal of Immunology</i> , 2001, 167, 5921-5927.	0.4	75
93	The Cyclic Adenosine 5'-Monophosphate Response Element Modulator Suppresses IL-2 Production in Stimulated T Cells by a Chromatin-Dependent Mechanism. <i>Journal of Immunology</i> , 2003, 170, 2971-2976.	0.4	75
94	Cyclic Adenosine 5'-Monophosphate Response Element Modulator Is Responsible for the Decreased Expression of c-fos and Activator Protein-1 Binding in T Cells from Patients with Systemic Lupus Erythematosus. <i>Journal of Immunology</i> , 2004, 173, 3557-3563.	0.4	74
95	Single-cell sequencing of immune cells from anticitrullinated peptide antibody positive and negative rheumatoid arthritis. <i>Nature Communications</i> , 2021, 12, 4977.	5.8	73
96	Phosphorylation and $\alpha$ -Linked Glycosylation of Elf-1 Leads to Its Translocation to the Nucleus and Binding to the Promoter of the TCR $\zeta$ -Chain. <i>Journal of Immunology</i> , 2002, 168, 2865-2871.	0.4	72
97	Immunopathogenesis of ischemia/reperfusion-associated tissue damage. <i>Clinical Immunology</i> , 2011, 141, 3-14.	1.4	72
98	Polymorphisms/Mutations of TCR $\zeta$ -Chain Promoter and 3' Untranslated Region and Selective Expression of TCR $\zeta$ -Chain with an Alternatively Spliced 3' Untranslated Region in Patients with Systemic Lupus Erythematosus. <i>Journal of Autoimmunity</i> , 2001, 16, 133-142.	3.0	71
99	Transcriptional Activation of the Human Inducible Nitric-oxide Synthase Promoter by Krüppel-like Factor 6. <i>Journal of Biological Chemistry</i> , 2003, 278, 14812-14819.	1.6	71
100	Functionally impaired plasmacytoid dendritic cells and non-haematopoietic sources of type I interferon characterize human autoimmunity. <i>Nature Communications</i> , 2020, 11, 6149.	5.8	71
101	Defective Fc $\gamma$ RIIIb1 Signaling Contributes to Enhanced Calcium Response in B Cells from Patients with Systemic Lupus Erythematosus. <i>Clinical Immunology</i> , 2001, 101, 130-135.	1.4	70
102	ZAP-70 and SLP-76 Regulate Protein Kinase C- $\delta$ and NF- $\kappa$ B Activation in Response to Engagement of CD3 and CD28. <i>Journal of Immunology</i> , 2001, 166, 5654-5664.	0.4	70
103	Methylation Status of CpG Islands Flanking a cAMP Response Element Motif on the Protein Phosphatase 2A $\alpha$ Promoter Determines CREB Binding and Activity. <i>Journal of Immunology</i> , 2009, 182, 1500-1508.	0.4	70
104	Decreased Stability and Translation of T Cell Receptor $\zeta$ mRNA with an Alternatively Spliced 3' Untranslated Region Contribute to $\zeta$ Chain Down-regulation in Patients with Systemic Lupus Erythematosus. <i>Journal of Biological Chemistry</i> , 2005, 280, 18959-18966.	1.6	68
105	Intracellular Activation of Complement 3 Is Responsible for Intestinal Tissue Damage during Mesenteric Ischemia. <i>Journal of Immunology</i> , 2017, 198, 788-797.	0.4	68
106	Generation and biochemical analysis of human effector CD4 T cells: alterations in tyrosine phosphorylation and loss of CD3 $\zeta$ expression. <i>Blood</i> , 2001, 97, 3851-3859.	0.6	67
107	T cell signaling abnormalities in systemic lupus erythematosus are associated with increased mutations/polymorphisms and splice variants of T cell receptor $\zeta$ chain messenger RNA. <i>Arthritis and Rheumatism</i> , 2001, 44, 1336-1350.	6.7	67
108	Increased Caspase-3 Expression and Activity Contribute to Reduced CD3 $\zeta$ Expression in Systemic Lupus Erythematosus T Cells. <i>Journal of Immunology</i> , 2005, 175, 3417-3423.	0.4	67

#	ARTICLE	IF	CITATIONS
109	Cutting Edge: Calcium/Calmodulin-Dependent Protein Kinase Type IV Is Essential for Mesangial Cell Proliferation and Lupus Nephritis. <i>Journal of Immunology</i> , 2011, 187, 5500-5504.	0.4	66
110	cAMP Responsive Element Modulator (CREM) $\hat{\pm}$ Mediates Chromatin Remodeling of CD8 during the Generation of CD3+CD4 $\hat{\sim}$ CD8 $\hat{\sim}$ T Cells. <i>Journal of Biological Chemistry</i> , 2014, 289, 2361-2370.	1.6	66
111	Glutaminase 1 Inhibition Reduces Glycolysis and Ameliorates Lupus $\hat{\sim}$ like Disease in <i>lpr</i> Mice and Experimental Autoimmune Encephalomyelitis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1869-1878.	2.9	66
112	Circulating Intercellular Adhesion Molecule-1 in Patients with Systemic Sclerosis. <i>Clinical Immunology and Immunopathology</i> , 1993, 68, 88-92.	2.1	65
113	Spleen tyrosine kinase inhibition in the treatment of autoimmune, allergic and autoinflammatory diseases. <i>Arthritis Research and Therapy</i> , 2010, 12, 222.	1.6	65
114	Promoter Hypomethylation Results in Increased Expression of Protein Phosphatase 2A in T Cells from Patients with Systemic Lupus Erythematosus. <i>Journal of Immunology</i> , 2011, 186, 4508-4517.	0.4	65
115	Increased Expression of SLAM Receptors SLAMF3 and SLAMF6 in Systemic Lupus Erythematosus T Lymphocytes Promotes Th17 Differentiation. <i>Journal of Immunology</i> , 2012, 188, 1206-1212.	0.4	65
116	ICER is requisite for Th17 differentiation. <i>Nature Communications</i> , 2016, 7, 12993.	5.8	64
117	Molecular aberrations in human systemic lupus erythematosus. <i>Trends in Molecular Medicine</i> , 2000, 6, 418-424.	2.6	63
118	Cytosolic DNA-Activated Human Dendritic Cells Are Potent Activators of the Adaptive Immune Response. <i>Journal of Immunology</i> , 2011, 187, 1222-1234.	0.4	63
119	Signaling Lymphocytic Activation Molecule Family Member 7 Engagement Restores Defective Effector CD8+ T Cell Function in Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2017, 69, 1035-1044.	2.9	63
120	Deficient $\hat{I}^3$ -interferon production in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1986, 29, 1210-1215.	6.7	62
121	Targeting Syk in Autoimmune Rheumatic Diseases. <i>Frontiers in Immunology</i> , 2016, 7, 78.	2.2	62
122	Characterization of murine complement receptor type 2 and its immunological cross-reactivity with type 1 receptor. <i>International Immunology</i> , 1990, 2, 651-659.	1.8	61
123	Increased Expression of Functional Fas-Ligand in Activated T Cells from Patients with Systemic Lupus Erythematosus. <i>Autoimmunity</i> , 1997, 25, 213-221.	1.2	61
124	Antiinflammatory Effects of Soluble Complement Receptor Type 1 Promote Rapid Recovery of Ischemia/Reperfusion Injury in Rat Small Intestine. <i>Clinical Immunology</i> , 1999, 90, 266-275.	1.4	61
125	Calcium signaling in systemic lupus erythematosus T cells: A treatment target. <i>Arthritis and Rheumatism</i> , 2011, 63, 2058-2066.	6.7	61
126	cAMP-responsive Element Modulator $\hat{I}^{\pm}$ (CREM $\hat{I}^{\pm}$ ) Suppresses IL-17F Protein Expression in T Lymphocytes from Patients with Systemic Lupus Erythematosus (SLE). <i>Journal of Biological Chemistry</i> , 2012, 287, 4715-4725.	1.6	61



#	ARTICLE	IF	CITATIONS
127	The Transcriptional Repressor cAMP Response Element Modulator $\hat{\pm}$ Interacts with Histone Deacetylase 1 to Repress Promoter Activity. <i>Journal of Immunology</i> , 2006, 177, 6159-6164.	0.4	60
128	KN-93, an inhibitor of calcium/calmodulin-dependent protein kinase IV, promotes generation and function of Foxp3 <sup>+</sup> regulatory T cells in MRL/lpr mice. <i>Autoimmunity</i> , 2014, 47, 445-450.	1.2	60
129	Immune cell signaling in lupus. <i>Current Opinion in Rheumatology</i> , 2000, 12, 355-363.	2.0	59
130	Epigenetic regulation of cytokine expression in systemic lupus erythematosus with special focus on T cells. <i>Autoimmunity</i> , 2014, 47, 234-241.	1.2	59
131	Systemic lupus erythematosus favors the generation of IL-17 producing double negative T cells. <i>Nature Communications</i> , 2020, 11, 2859.	5.8	59
132	Splicing factor SRSF1 controls T cell hyperactivity and systemic autoimmunity. <i>Journal of Clinical Investigation</i> , 2019, 129, 5411-5423.	3.9	59
133	Interleukin-2 and regulatory T cells in rheumatic diseases. <i>Nature Reviews Rheumatology</i> , 2021, 17, 749-766.	3.5	59
134	Immunohistological Demonstration of Transforming Growth Factor- $\hat{2}$ Isoforms in the Skin of Patients with Systemic Sclerosis. <i>Clinical Immunology and Immunopathology</i> , 1993, 69, 199-204.	2.1	58
135	Abnormal expression of various molecular forms and distribution of T cell receptor $\gamma$ chain in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2002, 46, 163-174.	6.7	58
136	The role of T cells in systemic lupus erythematosus. <i>Current Opinion in Rheumatology</i> , 2014, 26, 493-501.	2.0	58
137	Defective antigen-presenting cell function in patients with systemic lupus erythematosus: Role of the B7-1 (CD80) costimulatory molecule. <i>Arthritis and Rheumatism</i> , 1996, 39, 600-609.	6.7	57
138	T Cell Rewiring in Differentiation and Disease. <i>Journal of Immunology</i> , 2003, 171, 3325-3331.	0.4	57
139	Human Lupus Serum Induces Neutrophil-Mediated Organ Damage in Mice That Is Enabled by Mac-1 Deficiency. <i>Journal of Immunology</i> , 2012, 189, 3714-3723.	0.4	57
140	Protein Kinase C- $\hat{1}$ , Participates in the Activation of Cyclic AMP-Responsive Element-Binding Protein and Its Subsequent Binding to the $\hat{\alpha}$ 180 Site of the IL-2 Promoter in Normal Human T Lymphocytes. <i>Journal of Immunology</i> , 2001, 166, 5665-5674.	0.4	56
141	Targeting Regulatory T Cells to Treat Patients With Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , 2018, 9, 786.	2.2	56
142	A High-Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid Repurposing for Acute Lung Injury. <i>Cell Reports Medicine</i> , 2020, 1, 100137.	3.3	56
143	Deficiency of base excision repair enzyme NEIL3 drives increased predisposition to autoimmunity. <i>Journal of Clinical Investigation</i> , 2016, 126, 4219-4236.	3.9	56
144	Inhibition of SHP2 ameliorates the pathogenesis of systemic lupus erythematosus. <i>Journal of Clinical Investigation</i> , 2016, 126, 2077-2092.	3.9	56

#	ARTICLE	IF	CITATIONS
145	Pituitary-Adrenal Responsiveness to Corticotropin-Releasing Hormone in Patients Receiving Chronic, Alternate Day Glucocorticoid Therapy*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1985, 61, 22-27.	1.8	55
146	Transcriptional Activation of the cAMP-responsive Modulator Promoter in Human T Cells Is Regulated by Protein Phosphatase 2A-mediated Dephosphorylation of SP-1 and Reflects Disease Activity in Patients with Systemic Lupus Erythematosus. <i>Journal of Biological Chemistry</i> , 2011, 286, 1795-1801.	1.6	55
147	Complement 3d: From molecular adjuvant to target of immune escape mechanisms. <i>Clinical Immunology</i> , 2006, 121, 177-185.	1.4	54
148	Cell-Derived Extracellular Matrix-Rich Biomimetic Substrate Supports Podocyte Proliferation, Differentiation, and Maintenance of Native Phenotype. <i>Advanced Functional Materials</i> , 2020, 30, 1908752.	7.8	54
149	C5a causes limited, polymorphonuclear cell-independent, mesenteric ischemia/reperfusion-induced injury. <i>Clinical Immunology</i> , 2003, 108, 263-273.	1.4	53
150	cAMP-responsive Element Modulator 1 (CREM1) trans-Represses the Transmembrane Glycoprotein CD8 and Contributes to the Generation of CD3+CD4 <sup>hi</sup> CD8 <sup>lo</sup> T Cells in Health and Disease. <i>Journal of Biological Chemistry</i> , 2013, 288, 31880-31887.	1.6	53
151	Cutting Edge: Nanogel-Based Delivery of an Inhibitor of CaMK4 to CD4+ T Cells Suppresses Experimental Autoimmune Encephalomyelitis and Lupus-like Disease in Mice. <i>Journal of Immunology</i> , 2015, 195, 5533-5537.	0.4	53
152	Programmed Cell Death 1 and Helios Distinguish TCR <sup>hi</sup> CD4 <sup>lo</sup> Double-Negative (CD4 <sup>hi</sup> CD8 <sup>lo</sup> ) T Cells That Derive from Self-Reactive CD8 T Cells. <i>Journal of Immunology</i> , 2015, 194, 4207-4214.	0.4	53
153	Selective Loss of Signaling Lymphocytic Activation Molecule Family Member 4 <sup>hi</sup> Positive CD8+ T Cells Contributes to the Decreased Cytotoxic Cell Activity in Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2016, 68, 164-173.	2.9	53
154	PP2A Dephosphorylates Elf-1 and Determines the Expression of CD3 <sup>hi</sup> and FcR <sup>hi</sup> in Human Systemic Lupus Erythematosus T Cells. <i>Journal of Immunology</i> , 2008, 181, 3658-3664.	0.4	52
155	Glucocorticoids Suppress T Cell Function by Up-Regulating MicroRNA-98. <i>Arthritis and Rheumatism</i> , 2013, 65, 1882-1890.	6.7	52
156	T Cell Abnormalities in the Pathogenesis of Systemic Lupus Erythematosus: an Update. <i>Current Rheumatology Reports</i> , 2021, 23, 12.	2.1	52
157	Safety and efficacy of fecal microbiota transplantation for treatment of systemic lupus erythematosus: An EXPLORER trial. <i>Journal of Autoimmunity</i> , 2022, 130, 102844.	3.0	52
158	Lupus Serum IgG Induces Skin Inflammation through the TNFR1 Signaling Pathway. <i>Journal of Immunology</i> , 2010, 184, 7154-7161.	0.4	51
159	Cutting Edge: Protein Phosphatase 2A Confers Susceptibility to Autoimmune Disease through an IL-17 <sup>hi</sup> Dependent Mechanism. <i>Journal of Immunology</i> , 2012, 188, 3567-3571.	0.4	51
160	Estrogen Upregulates Cyclic AMP Response Element Modulator 1 Expression and Downregulates Interleukin-2 Production by Human T Lymphocytes. <i>Molecular Medicine</i> , 2012, 18, 370-378.	1.9	51
161	Splicing factor SF2/ASF rescues IL-2 production in T cells from systemic lupus erythematosus patients by activating IL-2 transcription. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 1845-1850.	3.3	51
162	Pathogenesis and targeted treatment of skin injury in SLE. <i>Nature Reviews Rheumatology</i> , 2015, 11, 663-669.	3.5	51

#	ARTICLE	IF	CITATIONS
163	Brief Report: CD4+ T Cells From Patients With Systemic Lupus Erythematosus Respond Poorly to Exogenous Interleukin-2. <i>Arthritis and Rheumatology</i> , 2017, 69, 808-813.	2.9	51
164	Pyruvate dehydrogenase phosphatase catalytic subunit 2 limits Th17 differentiation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 9288-9293.	3.3	51
165	The Structural Basis of Compstatin Activity Examined by Structure-Function-based Design of Peptide Analogs and NMR. <i>Journal of Biological Chemistry</i> , 2002, 277, 14942-14953.	1.6	50
166	Geldanamycin treatment inhibits hemorrhage-induced increases in KLF6 and iNOS expression in unresuscitated mouse organs: role of inducible HSP70. <i>Journal of Applied Physiology</i> , 2004, 97, 564-569.	1.2	50
167	Lupus Nephritis IgG Induction of Calcium/Calmodulin-Dependent Protein Kinase IV Expression in Podocytes and Alteration of Their Function. <i>Arthritis and Rheumatology</i> , 2016, 68, 944-952.	2.9	50
168	Accelerated Ischemia/Reperfusion-Induced Injury in Autoimmunity-Prone Mice. <i>Journal of Immunology</i> , 2004, 173, 4230-4235.	0.4	49
169	Empowering Regulatory T Cells in Autoimmunity. <i>Trends in Molecular Medicine</i> , 2016, 22, 784-797.	3.5	49
170	Neutrophil Fc $\gamma$ 3RIIA promotes IgG-mediated glomerular neutrophil capture via Abl/Src kinases. <i>Journal of Clinical Investigation</i> , 2017, 127, 3810-3826.	3.9	48
171	Site-specific PEGylation of interleukin-2 enhances immunosuppression via the sustained activation of regulatory T cells. <i>Nature Biomedical Engineering</i> , 2021, 5, 1288-1305.	11.6	47
172	A clinical and pathologic study of cerebrovascular disease in patients with systemic lupus erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , 1986, 16, 70-78.	1.6	46
173	Alternative Splicing Factor/Splicing Factor 2 Regulates the Expression of the $\beta$ Subunit of the Human T Cell Receptor-associated CD3 Complex. <i>Journal of Biological Chemistry</i> , 2010, 285, 12490-12496.	1.6	46
174	Induction of PP2A B $\beta$ , a regulator of IL-2 deprivation-induced T-cell apoptosis, is deficient in systemic lupus erythematosus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 12443-12448.	3.3	46
175	Treatment with Anti-Interleukin 23 Antibody Ameliorates Disease in Lupus-Prone Mice. <i>BioMed Research International</i> , 2013, 2013, 1-5.	0.9	46
176	Direct Transfer of p65 into T Lymphocytes from Systemic Lupus Erythematosus Patients Leads to Increased Levels of Interleukin-2 Promoter Activity. <i>Clinical Immunology</i> , 2002, 103, 145-153.	1.4	45
177	Systems biology in systemic lupus erythematosus: Integrating genes, biology and immune function. <i>Autoimmunity</i> , 2006, 39, 705-709.	1.2	45
178	Targeted tumor necrosis factor receptor I preligand assembly domain improves skin lesions in MRL- <i>lpr</i> mice. <i>Arthritis and Rheumatism</i> , 2010, 62, 2424-2431.	6.7	45
179	Spleen tyrosine kinase inhibition prevents tissue damage after ischemia-reperfusion. <i>American Journal of Physiology - Renal Physiology</i> , 2010, 299, G391-G399.	1.6	45
180	A quantitative lateral flow assay to detect complement activation in blood. <i>Analytical Biochemistry</i> , 2015, 477, 78-85.	1.1	45

#	ARTICLE	IF	CITATIONS
181	The Cyclic AMP Response Element Modulator Regulates Transcription of the TCR $\alpha$ -Chain. <i>Journal of Immunology</i> , 2005, 175, 5975-5980.	0.4	44
182	cAMP-responsive Element Modulator $\pm$ (CREM $\pm$ ) Contributes to Decreased Notch-1 Expression in T Cells from Patients with Active Systemic Lupus Erythematosus (SLE). <i>Journal of Biological Chemistry</i> , 2012, 287, 42525-42532.	1.6	44
183	T Cell Transcriptomes Describe Patient Subtypes in Systemic Lupus Erythematosus. <i>PLoS ONE</i> , 2015, 10, e0141171.	1.1	44
184	Successful Treatment of Generalized Discoid Skin Lesions With Azathioprine. <i>Archives of Dermatology</i> , 1985, 121, 1323.	1.7	43
185	Heterogeneous nuclear ribonucleoprotein D0B is a sequence-specific DNA-binding protein. <i>Biochemical Journal</i> , 1999, 338, 417-425.	1.7	43
186	Forced Expression of the Fc Receptor $\beta$ -Chain Renders Human T Cells Hyperresponsive to TCR/CD3 Stimulation. <i>Journal of Immunology</i> , 2003, 170, 2871-2876.	0.4	42
187	Transcriptional repression of interleukin-2 in human systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2006, 5, 118-121.	2.5	42
188	Spleen tyrosine kinase: An Src family of non-receptor kinase has multiple functions and represents a valuable therapeutic target in the treatment of autoimmune and inflammatory diseases. <i>Autoimmunity</i> , 2010, 43, 48-55.	1.2	42
189	Precision DNA demethylation ameliorates disease in lupus-prone mice. <i>JCI Insight</i> , 2018, 3, .	2.3	42
190	Spleen Tyrosine Kinase (Syk) Regulates Systemic Lupus Erythematosus (SLE) T Cell Signaling. <i>PLoS ONE</i> , 2013, 8, e74550.	1.1	42
191	Novel molecular targets in the treatment of systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2008, 7, 256-261.	2.5	41
192	Systemic lupus erythematosus serum deposits C4d on red blood cells, decreases red blood cell membrane deformability, and promotes nitric oxide production. <i>Arthritis and Rheumatism</i> , 2011, 63, 503-512.	6.7	41
193	Calcium/Calmodulin-Dependent Kinase IV Facilitates the Recruitment of Interleukin-17-Producing Cells to Target Organs Through the CCR6/CCL20 Axis in Th17 Cell-Driven Inflammatory Diseases. <i>Arthritis and Rheumatology</i> , 2016, 68, 1981-1988.	2.9	41
194	Activation of classical and alternative complement pathways in the pathogenesis of lung injury in COVID-19. <i>Clinical Immunology</i> , 2021, 226, 108716.	1.4	41
195	Neuroendocrine Aspects of Chronic Fatigue Syndrome. <i>NeuroImmunoModulation</i> , 2004, 11, 65-74.	0.9	40
196	The serine/threonine protein phosphatase 2A controls autoimmunity. <i>Clinical Immunology</i> , 2018, 186, 38-42.	1.4	40
197	Lupus Nephritis and Other Autoimmune Features in Patients with Diabetes Mellitus Due to Autoantibody to Insulin Receptors. <i>Annals of Internal Medicine</i> , 1985, 102, 176.	2.0	39
198	Association of Deficient Type II Protein Kinase A Activity with Aberrant Nuclear Translocation of the RII $\beta$ Subunit in Systemic Lupus Erythematosus T Lymphocytes. <i>Journal of Immunology</i> , 2000, 165, 2830-2840.	0.4	39

#	ARTICLE	IF	CITATIONS
199	Effect of trichostatin A on human T cells resembles signaling abnormalities in T cells of patients with systemic lupus erythematosus: A new mechanism for TCR $\zeta$ chain deficiency and abnormal signaling. <i>Journal of Cellular Biochemistry</i> , 2002, 85, 459-469.	1.2	39
200	Human c1 esterase inhibitor attenuates murine mesenteric ischemia/reperfusion induced local organ injury. <i>Journal of Surgical Research</i> , 2003, 115, 247-256.	0.8	39
201	T cell abnormalities in human and mouse lupus: intrinsic and extrinsic. <i>Current Opinion in Rheumatology</i> , 2003, 15, 542-547.	2.0	39
202	T lymphocytes in systemic lupus erythematosus: an update. <i>Current Opinion in Rheumatology</i> , 2004, 16, 548-552.	2.0	39
203	B cells contribute to ischemia/reperfusion-mediated tissue injury. <i>Journal of Autoimmunity</i> , 2009, 32, 195-200.	3.0	39
204	Ubiquitination Regulates Expression of the Serine/Arginine-rich Splicing Factor 1 (SRSF1) in Normal and Systemic Lupus Erythematosus (SLE) T Cells. <i>Journal of Biological Chemistry</i> , 2014, 289, 4126-4134.	1.6	39
205	Recent developments in systemic lupus erythematosus pathogenesis and applications for therapy. <i>Current Opinion in Rheumatology</i> , 2018, 30, 222-228.	2.0	39
206	The role of IL-17 in systemic lupus erythematosus and its potential as a therapeutic target. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 629-637.	1.3	39
207	Activation of the Ets Transcription Factor Elf1 Requires Phosphorylation and Glycosylation. <i>Annals of the New York Academy of Sciences</i> , 2003, 987, 240-245.	1.8	38
208	Effects of C1 Inhibitor on Tissue Damage in a Porcine Model of Controlled Hemorrhage. <i>Shock</i> , 2012, 38, 82-91.	1.0	38
209	Treatment of systemic lupus erythematosus: new advances in targeted therapy. <i>Annals of the New York Academy of Sciences</i> , 2012, 1247, 138-152.	1.8	38
210	Maintenance of Efficacy and Safety of Ustekinumab Through One Year in a Phase II Multicenter, Prospective, Randomized, Double-blind, Placebo-controlled Crossover Trial of Patients With Active Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2020, 72, 761-768.	2.9	38
211	Characterization of in Vivo Mutated T Cell Clones from Patients with Systemic Lupus Erythematosus. <i>Clinical Immunology and Immunopathology</i> , 1995, 74, 135-142.	2.1	37
212	Antibodies against p53 in sera from patients with systemic lupus erythematosus and other rheumatic diseases. <i>Arthritis and Rheumatism</i> , 1997, 40, 980-982.	6.7	37
213	C3d binding to the circumsporozoite protein carboxy-terminus deviates immunity against malaria. <i>International Immunology</i> , 2005, 17, 245-255.	1.8	37
214	Autoimmunity in systemic lupus erythematosus: Integrating genes and biology. <i>Seminars in Immunology</i> , 2006, 18, 230-243.	2.7	37
215	SLAMF6-driven co-stimulation of human peripheral T cells is defective in SLE T cells. <i>Autoimmunity</i> , 2011, 44, 211-218.	1.2	37
216	Low-Dose IL-2 in the Treatment of Lupus. <i>Current Rheumatology Reports</i> , 2016, 18, 68.	2.1	37

#	ARTICLE	IF	CITATIONS
217	Downregulation of miR-200a-3p, Targeting CtBP2 Complex, Is Involved in the Hypoproduction of IL-2 in Systemic Lupus Erythematosusâ€“Derived T Cells. <i>Journal of Immunology</i> , 2017, 198, 4268-4276.	0.4	37
218	The RNA-stabilizing Protein HuR Regulates the Expression of Î¶ Chain of the Human T Cell Receptor-associated CD3 Complex. <i>Journal of Biological Chemistry</i> , 2008, 283, 20037-20044.	1.6	36
219	Association of <i>PPP2CA</i> polymorphisms with systemic lupus erythematosus susceptibility in multiple ethnic groups. <i>Arthritis and Rheumatism</i> , 2011, 63, 2755-2763.	6.7	36
220	R-spondin3 prevents mesenteric ischemia/reperfusion-induced tissue damage by tightening endothelium and preventing vascular leakage. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 14348-14353.	3.3	36
221	Pro-inflammatory self-reactive T cells are found within murine TCR <sup>Î±Î²</sup> CD4 <sup>+</sup> CD8 <sup>+</sup> PD <sup>1</sup> <sup>+</sup> cells. <i>European Journal of Immunology</i> , 2016, 46, 1383-1391.	1.6	36
222	The immune podocyte. <i>Current Opinion in Rheumatology</i> , 2019, 31, 167-174.	2.0	36
223	Complement Receptor 2 in the Regulation of the Immune Response. <i>Clinical Immunology and Immunopathology</i> , 1998, 88, 123-132.	2.1	35
224	C5 is required for CD49d expression on neutrophils and VCAM expression on vascular endothelial cells following mesenteric ischemia/reperfusionâ€“††The opinions contained herein are the private ones of the authors and are not to be construed as official policy or reflecting the views of the Department of Defense.. <i>Clinical Immunology</i> , 2003, 106, 55-64.	1.4	35
225	Anti-RNP immunity: Implications for tissue injury and the pathogenesis of connective tissue disease. <i>Autoimmunity Reviews</i> , 2007, 6, 232-236.	2.5	35
226	Syk kinase as a treatment target for therapy in autoimmune diseases. <i>Clinical Immunology</i> , 2007, 124, 235-237.	1.4	35
227	Towards the next generation of anti-TNF drugs. <i>Clinical Immunology</i> , 2011, 141, 231-235.	1.4	35
228	The role of CD8+ T-cell systemic lupus erythematosus pathogenesis: an update. <i>Current Opinion in Rheumatology</i> , 2021, 33, 586-591.	2.0	35
229	Interplay of immune and kidney resident cells in the formation of tertiary lymphoid structures in lupus nephritis. <i>Autoimmunity Reviews</i> , 2021, 20, 102980.	2.5	35
230	Dissociation between Cortisol and Adrenal Androgen Secretion in Patients Receiving Alternate Day Prednisone Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1987, 65, 24-29.	1.8	34
231	Monoclonal antibodies and fusion proteins in medicine. <i>Journal of Allergy and Clinical Immunology</i> , 2005, 116, 721-729.	1.5	34
232	T cells and in situ cryoglobulin deposition in the pathogenesis of lupus nephritis. <i>Clinical Immunology</i> , 2008, 128, 1-7.	1.4	34
233	Dendritic cell function in lupus: Independent contributors or victims of aberrant immune regulation. <i>Autoimmunity</i> , 2010, 43, 121-130.	1.2	34
234	CREM <sup>Î±</sup> overexpression decreases IL-2 production, induces a TH17 phenotype and accelerates autoimmunity. <i>Journal of Molecular Cell Biology</i> , 2012, 4, 121-123.	1.5	34

#	ARTICLE	IF	CITATIONS
235	SLAMF6 as a Regulator of Exhausted CD8+ T Cells in Cancer. <i>Cancer Immunology Research</i> , 2019, 7, 1485-1496.	1.6	34
236	Aberrantly glycosylated IgG elicits pathogenic signaling in podocytes and signifies lupus nephritis. <i>JCI Insight</i> , 2021, 6, .	2.3	34
237	Double-negative T cells in autoimmune diseases. <i>Current Opinion in Rheumatology</i> , 2021, 33, 163-172.	2.0	34
238	SAP expression in invariant NKT cells is required for cognate help to support B-cell responses. <i>Blood</i> , 2012, 120, 122-129.	0.6	33
239	A T cell gene expression panel for the diagnosis and monitoring of disease activity in patients with systemic lupus erythematosus. <i>Clinical Immunology</i> , 2014, 150, 192-200.	1.4	33
240	TNF-Î± Regulates Human Plasmacytoid Dendritic Cells by Suppressing IFN-Î± Production and Enhancing T Cell Activation. <i>Journal of Immunology</i> , 2021, 206, 785-796.	0.4	33
241	IL-23 reshapes kidney resident cell metabolism and promotes local kidney inflammation. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	33
242	Is there a link between dysregulated miRNA expression and disease?. <i>Discovery Medicine</i> , 2010, 10, 184-94.	0.5	33
243	Heterogeneous nuclear ribonucleoprotein D0 contains transactivator and DNA-binding domains. <i>Biochemical Journal</i> , 2000, 348, 151-158.	1.7	32
244	Spontaneous and pokeweed mitogen-induced plaque-forming cells in systemic lupus erythematosus. <i>Clinical Immunology and Immunopathology</i> , 1981, 21, 172-183.	2.1	31
245	Immunomodulatory treatment in patients with rheumatic diseases: Mechanisms of action. <i>Seminars in Arthritis and Rheumatism</i> , 1987, 17, 24-38.	1.6	31
246	Cd28 expression on t cell subsets in vivo and cd28-mediated t cell response in vitro in patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1995, 38, 649-654.	6.7	31
247	Decay accelerating factor (CD55) protects neuronal cells from chemical hypoxia-induced injury. <i>Journal of Neuroinflammation</i> , 2010, 7, 24.	3.1	31
248	Complement and coagulation cascades in trauma. <i>Acute Medicine &amp; Surgery</i> , 2019, 6, 329-335.	0.5	31
249	Interleukin-2 restores the depressed allogeneic cell-mediated lympholysis and natural killer cell activity in patients with systemic lupus erythematosus. <i>Clinical Immunology and Immunopathology</i> , 1985, 34, 379-386.	2.1	30
250	Development of hypogammaglobulinemia in a patient with systemic lupus erythematosus. <i>American Journal of Medicine</i> , 1986, 81, 1081-1084.	0.6	30
251	Evidence that production of autoantibody to the alternative pathway C3 convertase is a normal physiologic event. <i>Journal of Pediatrics</i> , 1990, 116, S103-S108.	0.9	30
252	Decay-accelerating factor attenuates remote ischemiaâ€™reperfusion-initiated organ damage. <i>Clinical Immunology</i> , 2007, 124, 311-327.	1.4	30

#	ARTICLE	IF	CITATIONS
253	Common variable immune deficiency (CVID) presenting as an autoimmune disease: role of memory B cells. <i>Autoimmunity Reviews</i> , 2008, 7, 309-312.	2.5	30
254	A Novel Inhibitor of the Alternative Pathway of Complement Attenuates Intestinal Ischemia/Reperfusion-Induced Injury. <i>Journal of Surgical Research</i> , 2011, 167, e131-e136.	0.8	30
255	Impaired receptor editing and heterozygous RAG2 mutation in a patient with systemic lupus erythematosus and erosive arthritis. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 272-273.	1.5	30
256	Engagement of SLAMF3 enhances CD4 <sup>+</sup> T-cell sensitivity to IL-2 and favors regulatory T-cell polarization in systemic lupus erythematosus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 9321-9326.	3.3	30
257	Gene therapy in the treatment of autoimmune diseases. <i>Journal of Clinical Investigation</i> , 2000, 106, 181-183.	3.9	30
258	Lymphocytes, cytokines, inflammation, and immune trafficking. <i>Current Opinion in Rheumatology</i> , 1998, 10, 417-425.	2.0	29
259	Regulation of heat shock protein 72 kDa and 90 kDa in human breast cancer MDA-MB-231 cells. <i>Molecular and Cellular Biochemistry</i> , 2000, 204, 169-178.	1.4	29
260	TRANSCRIPTIONAL REGULATION OF INTERLEKIN 2 IN SLE T CELLS. <i>International Reviews of Immunology</i> , 2004, 23, 333-345.	1.5	29
261	Gammalinolenic Acid and Dihomogammalinolenic Acid Suppress the CD3-Mediated Signal Transduction Pathway in Human T Cells. <i>Clinical Immunology and Immunopathology</i> , 1997, 83, 237-244.	2.1	28
262	Heat stress protection against mesenteric I/R-induced alterations in intestinal mucosa in rats. <i>Journal of Applied Physiology</i> , 2002, 92, 2600-2607.	1.2	28
263	Protein Kinase A Regulatory Subunit Type II $\beta$ Directly Interacts with and Suppresses CREB Transcriptional Activity in Activated T Cells. <i>Journal of Immunology</i> , 2003, 171, 3636-3644.	0.4	28
264	A Novel Intronic cAMP Response Element Modulator (CREM) Promoter Is Regulated by Activator Protein-1 (AP-1) and Accounts for Altered Activation-induced CREM Expression in T Cells from Patients with Systemic Lupus Erythematosus. <i>Journal of Biological Chemistry</i> , 2011, 286, 32366-32372.	1.6	28
265	The Role of Platelet Factor 4 in Local and Remote Tissue Damage in a Mouse Model of Mesenteric Ischemia/Reperfusion Injury. <i>PLoS ONE</i> , 2012, 7, e39934.	1.1	28
266	Update on the role of Interleukin 17 in rheumatologic autoimmune diseases. <i>Cytokine</i> , 2015, 75, 207-215.	1.4	28
267	NF- $\kappa$ B Regulates the Expression of the Human Complement Receptor 2 Gene. <i>Journal of Immunology</i> , 2002, 169, 6236-6243.	0.4	27
268	Autoimmunity, Complement Activation, Tissue Injury and Reciprocal Effects. , 2003, 7, 149-164.		27
269	Complement Activation in Trauma Patients Alters Platelet Function. <i>Shock</i> , 2016, 46, 83-88.	1.0	27
270	Expression patterns of signaling lymphocytic activation molecule family members in peripheral blood mononuclear cell subsets in patients with systemic lupus erythematosus. <i>PLoS ONE</i> , 2017, 12, e0186073.	1.1	27



#	ARTICLE	IF	CITATIONS
271	Platelets orchestrate remote tissue damage after mesenteric ischemia-reperfusion. <i>American Journal of Physiology - Renal Physiology</i> , 2012, 302, G888-G897.	1.6	26
272	Current Insights and Future Prospects for Targeting IL-17 to Treat Patients With Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , 2020, 11, 624971.	2.2	26
273	Multiple Transcription Factors Regulate the Inducible Expression of the Human Complement Receptor 2 Promoter. <i>Journal of Immunology</i> , 2001, 166, 6156-6163.	0.4	25
274	New insights into the pathogenesis of systemic lupus erythematosus. <i>Current Rheumatology Reports</i> , 2005, 7, 469-475.	2.1	25
275	The Cyclic AMP Response Element Modulator $\hat{\pm}$ Suppresses CD86 Expression and APC Function. <i>Journal of Immunology</i> , 2009, 182, 4167-4174.	0.4	25
276	T Cell CD3 $\hat{\eta}$ Deficiency Enables Multiorgan Tissue Inflammation. <i>Journal of Immunology</i> , 2013, 191, 3563-3567.	0.4	25
277	Complement receptor of the immunoglobulin superfamily reduces murine lupus nephritis and cutaneous disease. <i>Clinical Immunology</i> , 2015, 160, 286-291.	1.4	25
278	Calcium/Calmodulin Kinase IV Controls the Function of Both T Cells and Kidney Resident Cells. <i>Frontiers in Immunology</i> , 2018, 9, 2113.	2.2	25
279	Cytoprotection and regulation of heat shock proteins induced by heat shock in human breast cancer T47 $\hat{\text{a}}$ cells: role of [Ca <sup>2+</sup> ] i and protein kinases. <i>FASEB Journal</i> , 1998, 12, 1571-1579.	0.2	24
280	Dexamethasone Modulates TCR $\hat{\eta}$ Chain Expression and Antigen Receptor-Mediated Early Signaling Events in Human T Lymphocytes. <i>Cellular Immunology</i> , 2001, 208, 62-71.	1.4	24
281	Intravenous immunoglobulin attenuates mesenteric ischemia $\hat{\text{a}}$ reperfusion injury. <i>Clinical Immunology</i> , 2005, 114, 137-146.	1.4	24
282	Ischemia-mediated aggregation of the actin cytoskeleton is one of the major initial events resulting in ischemia-reperfusion injury. <i>American Journal of Physiology - Renal Physiology</i> , 2009, 296, G339-G347.	1.6	24
283	Targeting lymphocyte signaling pathways as a therapeutic approach to systemic lupus erythematosus. <i>Current Opinion in Rheumatology</i> , 2011, 23, 449-453.	2.0	24
284	Platelet-Associated CD40/CD154 Mediates Remote Tissue Damage after Mesenteric Ischemia/Reperfusion Injury. <i>PLoS ONE</i> , 2012, 7, e32260.	1.1	24
285	C4d Deposits on the Surface of RBCs in Trauma Patients and Interferes With Their Function*. <i>Critical Care Medicine</i> , 2014, 42, e364-e372.	0.4	24
286	N-WASP is required for B-cell $\hat{\text{a}}$ mediated autoimmunity in Wiskott-Aldrich syndrome. <i>Blood</i> , 2016, 127, 216-220.	0.6	24
287	C3a Enhances the Formation of Intestinal Organoids through C3aR1. <i>Frontiers in Immunology</i> , 2017, 8, 1046.	2.2	24
288	New insights into the role of renal resident cells in the pathogenesis of lupus nephritis. <i>Korean Journal of Internal Medicine</i> , 2018, 33, 284-289.	0.7	24

#	ARTICLE	IF	CITATIONS
289	Cytotoxic antibodies to natural killer cells in systemic lupus erythematosus. <i>Clinical Immunology and Immunopathology</i> , 1982, 24, 179-185.	2.1	23
290	Production of IgG and IgM autoantibody to the alternative pathway C3 convertase in normal individuals and patients with membranoproliferative glomerulonephritis. <i>Clinical Immunology and Immunopathology</i> , 1990, 57, 10-18.	2.1	23
291	Lymphocytes, cytokines, inflammation, and immune trafficking. <i>Current Opinion in Rheumatology</i> , 1997, 9, 380-386.	2.0	23
292	Immune cell signaling aberrations in human lupus. <i>Immunologic Research</i> , 1998, 18, 27-39.	1.3	23
293	Genome-Wide Association Study Reveals Genetic Link between Diarrhea-Associated <i>Entamoeba histolytica</i> Infection and Inflammatory Bowel Disease. <i>MBio</i> , 2018, 9, .	1.8	23
294	Current insights and future prospects for the pathogenesis and treatment for rheumatoid arthritis. <i>Clinical Immunology</i> , 2021, 225, 108680.	1.4	23
295	T cell Metabolism in Lupus. <i>Immunometabolism</i> , 2020, 2, .	0.7	23
296	Rheumatic disease syndromes associated with antibodies to the Ro (SS-A) ribonuclear protein. <i>Seminars in Arthritis and Rheumatism</i> , 1987, 16, 237-244.	1.6	22
297	Abnormal Early TCR/CD3-Mediated Signaling Events of a snRNP-Autoreactive Lupus T Cell Clone. <i>Clinical Immunology and Immunopathology</i> , 1998, 88, 305-310.	2.1	22
298	A disease with a complex pathogenesis. <i>Lancet, The</i> , 2001, 358, S65.	6.3	22
299	Protein kinase A enhances, whereas glycogen synthase kinase-3 $\beta$ inhibits, the activity of the exon 2-encoded transactivator domain of heterogeneous nuclear ribonucleoprotein D in a hierarchical fashion. <i>Biochemical Journal</i> , 2002, 363, 127.	1.7	22
300	Protein kinase A enhances, whereas glycogen synthase kinase-3 $\beta$ inhibits, the activity of the exon 2-encoded transactivator domain of heterogeneous nuclear ribonucleoprotein D in a hierarchical fashion. <i>Biochemical Journal</i> , 2002, 363, 127-136.	1.7	22
301	Systemic lupus erythematosus: new molecular targets. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, iii65-iii69.	0.5	22
302	Anti-ribonucleoprotein antibodies mediate enhanced lung injury following mesenteric ischemia/reperfusion in Rag-1 $^{-/-}$ mice. <i>Autoimmunity</i> , 2007, 40, 208-216.	1.2	22
303	C3d-defined complement receptor-binding peptide p28 conjugated to circumsporozoite protein provides protection against <i>Plasmodium berghei</i> . <i>Vaccine</i> , 2007, 25, 7732-7736.	1.7	22
304	Complement Component C5a Mediates Hemorrhage-Induced Intestinal Damage. <i>Journal of Surgical Research</i> , 2008, 150, 196-203.	0.8	22
305	Decay-Accelerating Factor Attenuates C-Reactive Protein-Potentiated Tissue Injury After Mesenteric Ischemia/Reperfusion. <i>Journal of Surgical Research</i> , 2011, 167, e103-e115.	0.8	22
306	CD3-T Cell Receptor Co-stimulation through SLAMF3 and SLAMF6 Receptors Enhances ROR $\gamma$ t Recruitment to the IL17A Promoter in Human T Lymphocytes. <i>Journal of Biological Chemistry</i> , 2012, 287, 38168-38177.	1.6	22

#	ARTICLE	IF	CITATIONS
307	Decay-accelerating factor limits hemorrhage-instigated tissue injury and improves resuscitation clinical parameters. <i>Journal of Surgical Research</i> , 2013, 179, 153-167.	0.8	22
308	New therapeutics in systemic lupus erythematosus. <i>Current Opinion in Rheumatology</i> , 2013, 25, 297-303.	2.0	22
309	Pin1-Targeted Therapy for Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2016, 68, 2503-2513.	2.9	22
310	The Regulatory Subunit PPP2R2A of PP2A Enhances Th1 and Th17 Differentiation through Activation of the GEF-H1/RhoA/ROCK Signaling Pathway. <i>Journal of Immunology</i> , 2021, 206, 1719-1728.	0.4	22
311	Therapeutic potential of interleukin-2 in autoimmune diseases. <i>Trends in Molecular Medicine</i> , 2022, 28, 596-612.	3.5	22
312	On the origin of C3 nephritic factor (antibody to the alternative pathway C3 convertase): Evidence for the Adam and Eve concept of autoantibody production. <i>Clinical Immunology and Immunopathology</i> , 1992, 64, 177-183.	2.1	21
313	Androstenediol inhibits the trauma-hemorrhage-induced increase in caspase-3 by downregulating the inducible nitric oxide synthase pathway. <i>Journal of Applied Physiology</i> , 2007, 102, 933-941.	1.2	21
314	Expansion of an osteopontin-expressing T follicular helper cell subset correlates with autoimmunity in B6.Sle1b mice and is suppressed by the H1 isoform of the Slamf6 receptor. <i>FASEB Journal</i> , 2013, 27, 3123-3131.	0.2	21
315	Lupus-Prone Mice Fail to Raise Antigen-Specific T Cell Responses to Intracellular Infection. <i>PLoS ONE</i> , 2014, 9, e111382.	1.1	21
316	Cathepsin K Deficiency Ameliorates Systemic Lupus Erythematosus-like Manifestations in Fas <sup>pr</sup> Mice. <i>Journal of Immunology</i> , 2017, 198, 1846-1854.	0.4	21
317	SLE-Associated Defects Promote Altered T Cell Function. <i>Critical Reviews in Immunology</i> , 2017, 37, 39-58.	1.0	21
318	cAMP Response Element Modulator $\hat{\pm}$ Induces Dual Specificity Protein Phosphatase 4 to Promote Effector T Cells in Juvenile-Onset Lupus. <i>Journal of Immunology</i> , 2019, 203, 2807-2816.	0.4	21
319	CD38 reduces mitochondrial fitness and cytotoxic T cell response against viral infection in lupus patients by suppressing mitophagy. <i>Science Advances</i> , 2022, 8, .	4.7	21
320	Immunoregulatory aberrations in patients with polyarticular juvenile rheumatoid arthritis. <i>Clinical Immunology and Immunopathology</i> , 1988, 47, 62-74.	2.1	20
321	NaCN-induced chemical hypoxia is associated with altered gene expression. <i>Molecular and Cellular Biochemistry</i> , 2003, 254, 211-216.	1.4	20
322	Geldanamycin prevents hemorrhage-induced ATP loss by overexpressing inducible HSP70 and activating pyruvate dehydrogenase. <i>American Journal of Physiology - Renal Physiology</i> , 2006, 291, G117-G127.	1.6	20
323	Transcription factor Ikaros Represses Protein Phosphatase 2A (PP2A) Expression through an Intronic Binding Site. <i>Journal of Biological Chemistry</i> , 2014, 289, 13751-13757.	1.6	20
324	Decreased Expression of Serine/Arginine-Rich Splicing Factor 1 in T Cells From Patients With Active Systemic Lupus Erythematosus Accounts for Reduced Expression of RasGRP1 and DNA Methyltransferase 1. <i>Arthritis and Rheumatology</i> , 2018, 70, 2046-2056.	2.9	20

#	ARTICLE	IF	CITATIONS
325	Reactive oxygen species: The Yin and Yang in (auto-)immunity. <i>Autoimmunity Reviews</i> , 2021, 20, 102869.	2.5	20
326	Phenotypes of T lymphocytes in systemic lupus erythematosus: Decreased cytotoxic/suppressor subpopulation is associated with deficient allogeneic cytotoxic responses rather than with concanavalin A-induced suppressor cells. <i>Clinical Immunology and Immunopathology</i> , 1983, 26, 267-276.	2.1	19
327	Oxidative stress is involved in the heat stress-induced downregulation of TCR $\hat{\eta}$ chain expression and TCR/CD3-mediated $[Ca^{2+}]_i$ response in human T-lymphocytes. <i>Cellular Immunology</i> , 2002, 215, 151-161.	1.4	19
328	Constitutive NO synthase regulates the $Na^+/Ca^{2+}$ exchanger in human T cells: Role of $[Ca^{2+}]_i$ and tyrosine phosphorylation. <i>Journal of Cellular Biochemistry</i> , 2003, 89, 1030-1043.	1.2	19
329	Bridging the gap between autoinflammation and autoimmunity. <i>Clinical Immunology</i> , 2013, 147, 151-154.	1.4	19
330	Mood effects of alternate-day corticosteroid therapy in patients with systemic lupus erythematosus. <i>General Hospital Psychiatry</i> , 1988, 10, 56-60.	1.2	18
331	TCR- $\hat{\eta}$ / $\hat{\zeta}$ CD4 $\hat{\alpha}$ CD8 $\hat{\alpha}$ double negative T cells arise from CD8+ T cells. <i>Journal of Leukocyte Biology</i> , 2020, 108, 851-857.	1.5	18
332	Suppression of Serum Interferon- $\hat{\gamma}$ Levels as a Potential Measure of Response to Ustekinumab Treatment in Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2021, 73, 472-477.	2.9	18
333	Skeletal muscle heme oxygenase-1 activity regulates aerobic capacity. <i>Cell Reports</i> , 2021, 35, 109018.	2.9	18
334	PP2A enables IL-2 signaling by preserving IL-2R $\hat{\beta}$ chain expression during Treg development. <i>JCI Insight</i> , 2019, 4, .	2.3	18
335	The TRAIL to arthritis. <i>Journal of Clinical Investigation</i> , 2003, 112, 1315-1317.	3.9	18
336	Mitochondria in the Pathogenesis of Systemic Lupus Erythematosus. <i>Current Rheumatology Reports</i> , 2022, 24, 88-95.	2.1	18
337	Human anti-idiotypic antibody responses to autoantibody against the alternative pathway C3 convertase. <i>Clinical Immunology and Immunopathology</i> , 1990, 57, 19-31.	2.1	17
338	Elevated Soluble CD8 Antigen and Soluble Interleukin-2 Receptors in the Sera of Patients with Juvenile Rheumatoid Arthritis. <i>Clinical Immunology and Immunopathology</i> , 1993, 68, 64-67.	2.1	17
339	Biochemical requirements for the expression of heat shock protein 72 kda in human breast cancer MCF-7 cells. <i>Molecular and Cellular Biochemistry</i> , 1999, 199, 179-188.	1.4	17
340	Resuscitation with lactated Ringer solution limits the expression of molecular events associated with lung injury after hemorrhage. <i>Journal of Applied Physiology</i> , 2005, 98, 550-556.	1.2	17
341	Stability and Translation of TCR $\hat{\eta}$ mRNA Are Regulated by the Adenosine-Uridine-Rich Elements in Splice-Deleted 3 $\hat{\alpha}$ Untranslated Region of $\hat{\eta}$ -Chain. <i>Journal of Immunology</i> , 2006, 177, 8248-8257.	0.4	17
342	C5-blocking antibody reduces fluid requirements and improves responsiveness to fluid infusion in hemorrhagic shock managed with hypotensive resuscitation. <i>Journal of Applied Physiology</i> , 2007, 102, 673-680.	1.2	17

#	ARTICLE	IF	CITATIONS
343	Geldanamycin inhibits hemorrhage-induced increases in caspase-3 activity: role of inducible nitric oxide synthase. <i>Journal of Applied Physiology</i> , 2007, 103, 1045-1055.	1.2	17
344	Adhesion molecule expression precedes brain damages of lupus-prone mice and correlates with kidney pathology. <i>Journal of Neuroimmunology</i> , 2012, 252, 24-32.	1.1	17
345	Engagement of SLAMF2/CD48 Prolongs the Time Frame of Effective T Cell Activation by Supporting Mature Dendritic Cell Survival. <i>Journal of Immunology</i> , 2014, 192, 4436-4442.	0.4	17
346	Signaling Lymphocytic Activation Molecule Family Member 1 Engagement Inhibits T Cell-B Cell Interaction and Diminishes Interleukin-6 Production and Plasmablast Differentiation in Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019, 71, 99-108.	2.9	17
347	Gene-marked autologous hematopoietic stem cell transplantation of autoimmune disease. <i>Journal of Clinical Immunology</i> , 2000, 20, 1-9.	2.0	16
348	C1 Inhibitor Limits Organ Injury and Prolongs Survival in Swine Subjected to Battlefield Simulated Injury. <i>Shock</i> , 2016, 46, 177-188.	1.0	16
349	Complement activation and increased expression of Syk, mucin-1 and CaMK4 in kidneys of patients with COVID-19. <i>Clinical Immunology</i> , 2021, 229, 108795.	1.4	16
350	Pathogenesis of lupus nephritis: the contribution of immune and kidney resident cells. <i>Current Opinion in Rheumatology</i> , 2023, 35, 107-116.	2.0	16
351	Cytotoxic responses to alloantigens in systemic lupus erythematosus. <i>Journal of Clinical Immunology</i> , 1981, 1, 208-216.	2.0	15
352	Cellular immunity in patients with systemic juvenile rheumatoid arthritis. <i>Clinical Immunology and Immunopathology</i> , 1987, 42, 86-92.	2.1	15
353	Cell signaling and heat shock protein expression. <i>Journal of Biomedical Science</i> , 1996, 3, 379-388.	2.6	15
354	Heat stress downregulates TCR $\gamma$ chain expression in human T lymphocytes. <i>Journal of Cellular Biochemistry</i> , 2000, 79, 416-426.	1.2	15
355	Abnormal B Cell Signal Transduction in Systemic Lupus Erythematosus. , 2002, 6, 89-104.		15
356	Decay-Accelerating Factor Mitigates Controlled Hemorrhage-Instigated Intestinal and Lung Tissue Damage and Hyperkalemia in Swine. <i>Journal of Trauma</i> , 2011, 71, S151-S160.	2.3	15
357	Platelets, complement and tissue inflammation. <i>Autoimmunity</i> , 2013, 46, 1-5.	1.2	15
358	Metabolic control of T cells in autoimmunity. <i>Current Opinion in Rheumatology</i> , 2020, 32, 192-199.	2.0	15
359	Complement Deposition on the Surface of RBC After Trauma Serves a Biomarker of Moderate Trauma Severity: A Prospective Study. <i>Shock</i> , 2020, 53, 16-23.	1.0	15
360	Transcriptional and post-transcriptional mechanisms are responsible for the increased expression of c-myc protooncogene in lymphocytes from patients with systemic lupus erythematosus. <i>Clinical Immunology and Immunopathology</i> , 1989, 52, 507-515.	2.1	14

#	ARTICLE	IF	CITATIONS
361	Heterogeneous nuclear ribonucleoprotein D0B is a sequence-specific DNA-binding protein. <i>Biochemical Journal</i> , 1999, 338, 417.	1.7	14
362	Abnormal T Lymphocyte Signal Transduction in Systemic Lupus Erythematosus. , 2001, 5, 131-150.		14
363	N <sup>1</sup> %-nitro-l-arginine inhibits inducible HSP-70 via Ca <sup>2+</sup> , PKC, and PKA in human intestinal epithelial T84 cells. <i>American Journal of Physiology - Renal Physiology</i> , 2002, 282, G415-G423.	1.6	14
364	Down-Regulation of IL-2 Production in T Lymphocytes by Phosphorylated Protein Kinase A-R11 <sup>2</sup> . <i>Journal of Immunology</i> , 2004, 172, 7804-7812.	0.4	14
365	In the Beginning Was Sm. <i>Journal of Immunology</i> , 2006, 176, 1295-1296.	0.4	14
366	Why do women get lupus?. <i>Clinical Immunology</i> , 2012, 144, 53-56.	1.4	14
367	Metabolic control of arthritis: Switch pathways to treat. <i>Science Translational Medicine</i> , 2016, 8, 331fs8.	5.8	14
368	Decreased SAP Expression in T Cells from Patients with Systemic Lupus Erythematosus Contributes to Early Signaling Abnormalities and Reduced IL-2 Production. <i>Journal of Immunology</i> , 2016, 196, 4915-4924.	0.4	14
369	IL-17A Produced by Innate Lymphoid Cells Is Essential for Intestinal Ischemia-Reperfusion Injury. <i>Journal of Immunology</i> , 2017, 199, 2921-2929.	0.4	14
370	IL-23/IL-17 Axis in Inflammatory Rheumatic Diseases. <i>Clinical Reviews in Allergy and Immunology</i> , 2021, 60, 31-45.	2.9	14
371	PPP2R2D suppresses IL-2 production and Treg function. <i>JCI Insight</i> , 2020, 5, .	2.3	14
372	Efficacy and Safety of Ustekinumab in Patients With Active Systemic Lupus Erythematosus: Results of a Phase II Open-label Extension Study. <i>Journal of Rheumatology</i> , 2022, 49, 380-387.	1.0	14
373	Enhanced and sustained activation of human B cells by anti-immunoglobulin conjugated to the EBV glycoprotein gp350. <i>European Journal of Immunology</i> , 2000, 30, 969-973.	1.6	13
374	Exploring complement activation to develop biomarkers for systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2004, 50, 3404-3407.	6.7	13
375	Elf-1 Binds to GGAA Elements on the FcR <sup>1</sup> <sub>3</sub> Promoter and Represses Its Expression. <i>Journal of Immunology</i> , 2007, 179, 4884-4889.	0.4	13
376	Identification of Orch3, a Locus Controlling Dominant Resistance to Autoimmune Orchitis, as Kinesin Family Member 1C. <i>PLoS Genetics</i> , 2012, 8, e1003140.	1.5	13
377	CD74 Deficiency Mitigates Systemic Lupus Erythematosus-like Autoimmunity and Pathological Findings in Mice. <i>Journal of Immunology</i> , 2017, 198, 2568-2577.	0.4	13
378	CD25 and Protein Phosphatase 2A Cooperate to Enhance IL-2R Signaling in Human Regulatory T Cells. <i>Journal of Immunology</i> , 2019, 203, 93-104.	0.4	13

#	ARTICLE	IF	CITATIONS
379	N-glycosylated IgG in patients with kidney transplants increases calcium/calmodulin kinase IV in podocytes and causes injury. <i>American Journal of Transplantation</i> , 2021, 21, 148-160.	2.6	13
380	Serine Arginine-Rich Splicing Factor 1 (SRSF1) Contributes to the Transcriptional Activation of CD31 $\uparrow$ in Human T Cells. <i>PLoS ONE</i> , 2015, 10, e0131073.	1.1	13
381	Recovery of splenic function after gvhd-associated functional asplenia. <i>American Journal of Hematology</i> , 1982, 12, 77-80.	2.0	12
382	Human T-cell leukemia/lymphoma virus I and/or Epstein-Barr virus-infected B-cell lines spontaneously produce acid-labile $\gamma$ -interferon. <i>Journal of Clinical Immunology</i> , 1985, 5, 340-344.	2.0	12
383	Immunosuppressive Agents and Plasmapheresis in Immunological Disorders. <i>Immunopharmacology and Immunotoxicology</i> , 1985, 7, 1-15.	0.8	12
384	Human polyclonal and monoclonal IgG and IgM complement 3 nephritic factors: Evidence for idiotypic commonality. <i>Clinical Immunology and Immunopathology</i> , 1989, 53, 113-122.	2.1	12
385	The Role of Complement in the Antiphospholipid Syndrome-Associated Pathology. <i>Clinical Reviews in Allergy and Immunology</i> , 2009, 36, 141-144.	2.9	12
386	CREM1 $\pm$ suppresses spleen tyrosine kinase expression in normal but not systemic lupus erythematosus T cells. <i>Arthritis and Rheumatism</i> , 2012, 64, 799-807.	6.7	12
387	Downregulation of CD31 $\uparrow$ in NK Cells from Systemic Lupus Erythematosus Patients Confers a Proinflammatory Phenotype. <i>Journal of Immunology</i> , 2018, 200, 3077-3086.	0.4	12
388	Hyaluronic Acid Synthesis Contributes to Tissue Damage in Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , 2019, 10, 2172.	2.2	12
389	Curb complement to cure COVID-19. <i>Clinical Immunology</i> , 2020, 221, 108603.	1.4	12
390	Amino Acid Metabolism in Lupus. <i>Frontiers in Immunology</i> , 2021, 12, 623844.	2.2	12
391	OVERVIEW OF CELLULAR IMMUNE FUNCTION IN SYSTEMIC LUPUS ERYTHEMATOSUS. , 2004, , 29-92.		12
392	Spleen tyrosine kinase (Syk) inhibitor fostamatinib limits tissue damage and fibrosis in a bleomycin-induced scleroderma mouse model. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S15-22.	0.4	12
393	The deacetylase SIRT2 contributes to autoimmune disease pathogenesis by modulating IL-17A and IL-2 transcription. , 2022, 19, 738-750.		12
394	C-MYC proto-oncogene expression in peripheral blood mononuclear cells from patients with primary Sjögren's syndrome. <i>Arthritis and Rheumatism</i> , 1990, 33, 49-56.	6.7	11
395	Effects of an aminosteroid inhibitor of phospholipase C-dependent processes on the TCR-mediated signal transduction pathway in human T cells. <i>Clinical Immunology and Immunopathology</i> , 1995, 77, 59-68.	2.1	11
396	High dose of dexamethasone upregulates TCR/CD3-induced calcium response independent of TCR $\gamma$ chain expression in human T lymphocytes. <i>Journal of Cellular Biochemistry</i> , 2001, 83, 401-413.	1.2	11

#	ARTICLE	IF	CITATIONS
397	DISSECTING THE MOLECULAR MECHANISMS OF TCR $\hat{\gamma}$ CHAIN DOWNREGULATION AND T Cell SIGNALING ABNORMALITIES IN HUMAN SYSTEMIC LUPUS ERYTHEMATOSUS. <i>International Reviews of Immunology</i> , 2004, 23, 245-263.	1.5	11
398	Calcium signaling in systemic lupus erythematosus lymphocytes and its therapeutic exploitation. <i>Arthritis and Rheumatism</i> , 2008, 58, 1216-1219.	6.7	11
399	Cellular and metabolic requirements of effector T cells. <i>Nature Reviews Rheumatology</i> , 2016, 12, 74-76.	3.5	11
400	Editorial: Systemic Lupus Erythematosus and Antiphospholipid Syndrome. <i>Frontiers in Immunology</i> , 2019, 10, 199.	2.2	11
401	Cancer immunosurveillance by CD8 T cells. <i>F1000Research</i> , 2020, 9, 80.	0.8	11
402	Immune Abnormalities in the Pathogenesis of Juvenile Rheumatoid Arthritis. <i>Rheumatic Disease Clinics of North America</i> , 1991, 17, 843-857.	0.8	11
403	Epstein-Barr virus transformed B cell lines derived from patients with systemic lupus erythematosus produce a nephritic factor of the classical complement pathway. <i>Clinical Immunology and Immunopathology</i> , 1988, 46, 91-99.	2.1	10
404	Corticotropin-releasing factor induces phosphorylation of phospholipase C- $\hat{\beta}$ at tyrosine residues via its receptor $2\hat{I}^2$ in human epidermoid A-431 cells. <i>European Journal of Pharmacology</i> , 1998, 363, 203-210.	1.7	10
405	Diabetic Hyperglycemia: A Facilitating Factor in Systemic Capillary Leak. <i>Journal of Surgical Research</i> , 2002, 105, 95-101.	0.8	10
406	Inhibition of Syk activity by R788 in platelets prevents remote lung tissue damage after mesenteric ischemia-reperfusion injury. <i>American Journal of Physiology - Renal Physiology</i> , 2012, 302, G1416-G1422.	1.6	10
407	c-Jun and Ets2 Proteins Regulate Expression of Spleen Tyrosine Kinase in T Cells. <i>Journal of Biological Chemistry</i> , 2012, 287, 11833-11841.	1.6	10
408	What rheumatologists need to know about innate lymphocytes. <i>Nature Reviews Rheumatology</i> , 2016, 12, 658-668.	3.5	10
409	Signaling lymphocyte activation molecule family in systemic lupus erythematosus. <i>Clinical Immunology</i> , 2019, 204, 57-63.	1.4	10
410	Suppressor cells generated from human peripheral mononuclear cells by stimulation with pokeweed mitogen. <i>Cellular Immunology</i> , 1981, 65, 221-229.	1.4	9
411	Kinetics of interleukin-4 induction and interferon- $\hat{\beta}$ inhibition of IgE secretion by Epstein-Barr virus-infected human peripheral blood B cells. <i>Cellular Immunology</i> , 1991, 133, 408-419.	1.4	9
412	Nucleotide Sequence of a Human Autoantibody to the Alternative Pathway C3/C5 Convertase (C3NeF). <i>Hybridoma</i> , 1993, 12, 231-237.	0.9	9
413	Modulation of Human T-Lymphocyte Plasma Membrane Ca <sup>+2</sup> Permeability by Imidazole Antimycotics. <i>Immunopharmacology and Immunotoxicology</i> , 1996, 18, 237-245.	1.1	9
414	TCR $\hat{\gamma}$ -Chain Abnormalities in Human Systemic Lupus Erythematosus. , 2004, 102, 049-072.		9



#	ARTICLE	IF	CITATIONS
415	A114: Methylprednisolone-Induced Inhibition of miR-155 Expression Increases SOCS1-Driven Suppression of Cytokine Signaling. <i>Arthritis and Rheumatology</i> , 2014, 66, S151-S151.	2.9	9
416	Criteria, criteria all around but not an insight into lupus. <i>Rheumatology</i> , 2021, 60, 3037-3038.	0.9	9
417	Serine/threonine phosphatase PP2A is essential for optimal B cell function. <i>JCI Insight</i> , 2020, 5, .	2.3	9
418	Cholera toxin promotes the proliferation of anti-Î¼ antibody-prestimulated human B cells. <i>Cellular Immunology</i> , 1992, 140, 237-247.	1.4	8
419	Heterogeneous nuclear ribonucleoprotein D0 contains transactivator and DNA-binding domains. <i>Biochemical Journal</i> , 2000, 348, 151.	1.7	8
420	Defective CD3Î¶ chain expression in Herpesvirus saimiri (HVS)-derived T-cell lines in gastric adenocarcinoma. <i>Cellular Immunology</i> , 2005, 238, 113-122.	1.4	8
421	T cell-to-T cell clustering enhances NF-Î²B activity by a PI3K signal mediated by Cbl-b and Rho. <i>Biochemical and Biophysical Research Communications</i> , 2005, 332, 1133-1139.	1.0	8
422	ADAM9 enhances Th17 cell differentiation and autoimmunity by activating TGF-Î²1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	8
423	Aneurysm of the ascending aorta in systemic lupus erythematosus: Case report and review of the literature. <i>European Journal of Rheumatology</i> , 2017, 4, 133-135.	1.3	8
424	Role of Glutaminase 2 in Promoting CD4+ T Cell Production of Interleukin-2 by Supporting Antioxidant Defense in Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2022, 74, 1204-1210.	2.9	8
425	Intertwined pathways of complement activation command the pathogenesis of lupus nephritis. <i>Translational Research</i> , 2022, 245, 18-29.	2.2	8
426	Study of the idiotypic response to autoantibody to the alternative pathway convertase in normal individuals, patients with membranoproliferative glomerulonephritis, and experimental animals. <i>Clinical Immunology and Immunopathology</i> , 1992, 62, 291-294.	2.1	7
427	Overview of cellular immune function in systemic lupus erythematosus. , 2004, , 29-92.		7
428	Systemic lupus erythematosus: From disease pathogenesis to therapy. <i>Drug Discovery Today Disease Mechanisms</i> , 2006, 3, 185-192.	0.8	7
429	Proximal signaling control of human effector CD4 T cell function. <i>Clinical Immunology</i> , 2007, 125, 5-15.	1.4	7
430	Pathology and immunology of lupus glomerulonephritis: can we bridge the two?. <i>International Urology and Nephrology</i> , 2007, 39, 223-231.	0.6	7
431	Brief Report: Increased expression of a short splice variant of CTLA-4 exacerbates lupus in MRL- <i>lpr</i> mice. <i>Arthritis and Rheumatism</i> , 2013, 65, 764-769.	6.7	7
432	The role of Syk in cutaneous lupus erythematosus. <i>Experimental Dermatology</i> , 2016, 25, 674-675.	1.4	7

#	ARTICLE	IF	CITATIONS
433	Skin-kidney crosstalk in SLE. <i>Nature Reviews Rheumatology</i> , 2021, 17, 253-254.	3.5	7
434	Inhibition of capping of immunoglobulin and concanavalin A receptors by cis-dichlorodiammineplatinum-(II) in mouse spleen cells. <i>Cancer Letters</i> , 1980, 10, 261-267.	3.2	6
435	Induction of monocytic suppression after stimulation of peripheral human mononuclear cells with staphylococcal protein A and <i>Staphylococcus aureus</i> . <i>Cellular Immunology</i> , 1983, 78, 144-151.	1.4	6
436	Enhancement of Human Allogeneic Cytotoxic Responses by Interferons. <i>Immunopharmacology and Immunotoxicology</i> , 1985, 7, 403-415.	0.8	6
437	Pathogenesis of human systemic lupus erythematosus. <i>Clinical Immunology and Immunopathology</i> , 1992, 63, 3.	2.1	6
438	Gene Therapy in Systemic Lupus Erythematosus. <i>Current Gene Therapy</i> , 2005, 5, 677-684.	0.9	6
439	Fas (CD95) ligation inhibits activation of NF- $\kappa$ B by targeting p65-Rel A in a caspase-dependent manner. <i>Clinical Immunology</i> , 2006, 121, 47-53.	1.4	6
440	Immune cell signaling in autoimmune diseases. <i>Clinical Immunology</i> , 2017, 181, 1-8.	1.4	6
441	Low-dose Interleukin-2 in the Treatment of Autoimmune Disease. <i>Oncology &amp; Hematology Review</i> , 2014, 10, 157.	0.2	6
442	The TRAIL to arthritis. <i>Journal of Clinical Investigation</i> , 2003, 112, 1315-1317.	3.9	6
443	Lymphocyte subpopulations in patients with systemic lupus erythematosus. <i>Clinical Immunology and Immunopathology</i> , 1984, 31, 181-190.	2.1	5
444	Regulation of Human Cytotoxic Responses by Complement: C3, C3b and C3d Preparations Enhance Human Allogeneic Cytotoxic Responses. <i>Immunopharmacology and Immunotoxicology</i> , 1986, 8, 529-541.	1.1	5
445	Lymphocytes, cytokines, inflammation, and immune trafficking. <i>Current Opinion in Rheumatology</i> , 1994, 6, 461-467.	2.0	5
446	IDENTIFICATION OF DIFFERENTIALLY EXPRESSED GENES IN HUMAN MEMORY (CD45RO+) CD4+T LYMPHOCYTES. <i>Immunological Investigations</i> , 2001, 30, 87-101.	1.0	5
447	Uncovering the Genetics of Systemic Lupus Erythematosus. <i>Molecular Diagnosis and Therapy</i> , 2003, 3, 193-202.	3.3	5
448	New therapeutic approaches in systemic lupus erythematosus. <i>Current Opinion in Rheumatology</i> , 2021, 33, 181-189.	2.0	5
449	Protein phosphatase 2A B551 <sup>2</sup> limits CD8+ T cell lifespan following cytokine withdrawal. <i>Journal of Clinical Investigation</i> , 2020, 130, 5989-6004.	3.9	5
450	Inhibition of calcium/calmodulin-dependent protein kinase IV in arthritis: dual effect on Th17 cell activation and osteoclastogenesis. <i>Rheumatology</i> , 2023, 62, 861-871.	0.9	5

#	ARTICLE	IF	CITATIONS
451	A Factor Activating Complement via the Alternative Pathway in the Supernatants of B Cell Lines Transformed by Epstein-Barr Virus and in Sera Obtained from Patients with Systemic Lupus erythematosus. <i>International Archives of Allergy and Immunology</i> , 1988, 86, 209-214.	0.9	4
452	Heat-Shock of Normal T-Cells and T-Cell Lines Downregulates the TCR/CD3-Mediated Cytoplasmic CA2+Responses and the Production of Inositol Triphosphate. <i>Immunopharmacology and Immunotoxicology</i> , 1997, 19, 511-521.	1.1	4
453	FcR <sup>3</sup> chain does not replace CD3 <sup>1</sup> chain in CD3 <sup>1</sup> -deficient T lymphocytes of patients with gastric adenocarcinoma. <i>Molecular Immunology</i> , 2007, 44, 2400-2405.	1.0	4
454	Interleukin <sup>2</sup> in systemic autoimmunity hits the micro way. <i>Arthritis and Rheumatism</i> , 2012, 64, 3494-3497.	6.7	4
455	Monogenic lupus. <i>International Journal of Clinical Rheumatology</i> , 2014, 9, 543-546.	0.3	4
456	Cyclic AMP Response Element Modulator-1 <sup>2</sup> Suppresses PD-1 Expression and Promotes Effector CD4+ T Cells in Psoriasis. <i>Journal of Immunology</i> , 2021, 207, 55-64.	0.4	4
457	Alternate-Day Corticosteroid Treatment, Mood and Plasma HVA in Patients with Systemic Lupus erythematosus. <i>Neuropsychobiology</i> , 1988, 19, 17-19.	0.9	3
458	The CR2 receptor (CD21) shows increased expression in the more differentiated cells of an antigen-specific B cell line. <i>Cellular Immunology</i> , 1990, 125, 386-395.	1.4	3
459	Cytokines in Systemic Lupus Erythematosus 2011. <i>Journal of Biomedicine and Biotechnology</i> , 2012, 2012, 1-1.	3.0	3
460	Complement depletion protects lupus-prone mice from ischemia-reperfusion-initiated organ injury. <i>American Journal of Physiology - Renal Physiology</i> , 2013, 304, G283-G292.	1.6	3
461	B Cells in Systemic Lupus Erythematosus. , 1999, , 167-180.		3
462	Melanocyte-secreted fibromodulin constrains skin inflammation in mice injected with lupus serum. <i>Clinical Immunology</i> , 2022, , 109055.	1.4	3
463	Chlorpromazine and Lidocaine Inhibit Antibody-Dependent Cell-Mediated Cytotoxicity but Not Erythrocyte Antibody Rosette Formation. <i>International Archives of Allergy and Immunology</i> , 1980, 61, 344-346.	0.9	2
464	The Alter Ego of Heat Shock Proteins. <i>Clinical Immunology and Immunopathology</i> , 1998, 86, 235-236.	2.1	2
465	Characterization of Distinct Heat Shock- and Thapsigargin-Induced Cytoprotective Proteins in FRTL-5 Thyroid Cells. <i>Thyroid</i> , 1999, 9, 1041-1047.	2.4	2
466	Serum Regulates the Expression of Complement Receptor 2 on Human B Cell Lines. <i>Immunopharmacology and Immunotoxicology</i> , 2000, 22, 205-219.	1.1	2
467	IMMUNE CELL SIGNALING AND GENE TRANSCRIPTION IN HUMAN LUPUS: THE TIME HAS COME. <i>International Reviews of Immunology</i> , 2004, 23, 221-224.	1.5	2
468	Systemic lupus erythematosus and Sjögren's syndrome. <i>Current Opinion in Rheumatology</i> , 2005, 17, 511-512.	2.0	2

#	ARTICLE	IF	CITATIONS
469	Overview of the Pathogenesis of Systemic Lupus Erythematosus. , 2007, , 55-63.		2
470	Post-Transcriptional Regulation of T Cell Receptor zeta Chain in Systemic Lupus Erythematosus. Clinical Immunology, 2007, 123, S66.	1.4	2
471	Cytokines in Systemic Lupus Erythematosus. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-2.	3.0	2
472	T Cells. , 2013, , 96-103.		2
473	Nephritic Factor Autoantibodies. , 2014, , 561-565.		2
474	Fat T cells go to the joint. Nature Immunology, 2017, 18, 955-956.	7.0	2
475	OP0041â€¦MAINTENANCE OF EFFICACY AND SAFETY AND REDUCTION OF BILAG FLARES WITH USTEKINUMAB, AN INTERLEUKIN-12/23 INHIBITOR, IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): 1-YEAR RESULTS OF A PHASE 2, RANDOMIZED PLACEBO-CONTROLLED, CROSSOVER STUDY. , 2019, , .		2
476	251â€¦Type II but not type I interferon signifies clinical response to ustekinumab in patients with systemic lupus erythematosus. , 2019, , .		2
477	T Lymphocytes Cash Their Value in Clinical Medicine. Trends in Molecular Medicine, 2020, 26, 800-802.	3.5	2
478	FcÎ¼ receptor type I Î³ chain replaces the deficient T cell receptor Î¶ chain in T cells of patients with systemic lupus erythematosus. , 2001, 44, 1114.		2
479	Methods and Protocols to Study T Cell Signaling Abnormalities in Human Systemic Lupus Erythematosus. Methods in Molecular Biology, 2012, 900, 25-60.	0.4	2
480	The global burden of heterogeneity of lupus erythematosus interventional trials. Journal of Autoimmunity, 2022, 128, 102798.	3.0	2
481	Kidney-Draining Lymph Node Fibrosis Following Unilateral Ureteral Obstruction. Frontiers in Immunology, 2021, 12, 768412.	2.2	2
482	Lymphocytes in the neighborhood: good or bad for the kidney?. Journal of Clinical Investigation, 2022, 132, .	3.9	2
483	Ikaros, Aiolos and other moving targets to treat SLE. Nature Reviews Rheumatology, 2022, 18, 499-500.	3.5	2
484	Immune Cell Signaling and Gene Transcription in Human Systemic Lupus Erythematosus. , 2005, , 263-278.		1
485	Complement in autoimmunity and tissue injury. Autoimmunity, 2006, 39, 355-356.	1.2	1
486	The Role of Interleukin-17 in Systemic Lupus Erythematosus. , 2011, , 391-400.		1

#	ARTICLE	IF	CITATIONS
487	Target It All Right, But Do Not Forget the Torchbearer. <i>Circulation</i> , 2015, 131, 1153-1155.	1.6	1
488	OP0278â€¦BIOMARKER PROFILING REVEALS NOVEL MECHANISTIC INSIGHTS INTO USTEKINUMAB THERAPEUTIC RESPONSES IN SYSTEMIC LUPUS ERYTHEMATOSUS. , 2019, , .		1
489	SNPs talk to genes using landlines: long-range chromatin interactions link genetic risk with epigenetic patterns in Takayasu arteritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1293-1295.	0.5	1
490	A new checkpoint in lupus. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 1351-1352.	1.5	1
491	Animal Models: Systemic Autoimmune Diseases. , 2020, , 533-551.		1
492	Notch notches lupus. <i>Kidney International</i> , 2020, 97, 251-253.	2.6	1
493	Pathogenesis of lupus. , 2011, , 1289-1294.e1.		1
494	Nephritic Factor Autoantibodies. , 1996, , 540-545.		1
495	Animal Models of Autoimmune Disease. , 2006, , 329-348.		1
496	TARGETING TARGETED TREATMENT FOR IMMUNE AND NON-IMMUNE KIDNEY DISEASES. <i>Transactions of the American Clinical and Climatological Association</i> , 2019, 130, 88-99.	0.9	1
497	Shortage of aspartate in mitochondria fuels arthritis. <i>Nature Immunology</i> , 2021, 22, 1474-1476.	7.0	1
498	Tissue resident cell processes determine organ damage in systemic lupus erythematosus. <i>Clinical Immunology</i> , 2022, 234, 108919.	1.4	1
499	Reduction of Cell Surface T-Cell Receptor by Non-Mitogenic CD3 Antibody to Mitigate Murine Lupus. <i>Frontiers in Immunology</i> , 2022, 13, 855812.	2.2	1
500	Treatment of Discoid Skin Lesions With Azathioprine-Reply. <i>Archives of Dermatology</i> , 1986, 122, 746.	1.7	0
501	Inhibition of ischemia reperfusion-induced intestinal injury and systemic inflammation by a novel complement regulatory protein. <i>Gastroenterology</i> , 2000, 118, A829.	0.6	0
502	Role of HSP70I in heat stress and glutamine protection against mesenteric ischemia/reperfusion (IR)-induced injury in vivo. <i>Gastroenterology</i> , 2000, 118, A1123.	0.6	0
503	Regulation of Complement Receptor Gene Expression. , 2004, , 61-73.		0
504	Role of Complement in Intestinal Ischemia/Reperfusion Induced Injury. , 2004, , 437-449.		0

#	ARTICLE	IF	CITATIONS
505	Complement and Autoimmunity. , 2004, , 307-314.		0
506	SLE and Sjögren syndrome in 2004. Current Opinion in Rheumatology, 2004, 16, 497-498.	2.0	0
507	Systemic Lupus Erythematosus: New Ideas for Diagnosis and Treatment. , 2006, , 249-270.		0
508	NEPHRITIC FACTOR AUTOANTIBODIES. , 2007, , 561-566.		0
509	2006 clinical immunology school on systemic autoimmune diseases. Autoimmunity Reviews, 2007, 6, 203.	2.5	0
510	Sa.5. The Role of Lipid Rafts in the Pathogenesis of Systemic Lupus Erythematosus. Clinical Immunology, 2008, 127, S81.	1.4	0
511	Sa.45. Alternative Splicing Factor/Splicing Factor 2 (ASF/SF2) Regulates the Expression of T Cell Receptor $\alpha$ chain. Clinical Immunology, 2008, 127, S95.	1.4	0
512	Sa.99. CREB Binds to Demethylated CRE-elements on the PP2A $\beta$ Promoter and Induces Its Expression. Clinical Immunology, 2008, 127, S113.	1.4	0
513	T-Cells and Systemic Lupus Erythematosus. , 2011, , 129-142.		0
514	In appreciation of Patricia Katz, PhD and Edward Yelin, PhD, Co-Editors, Arthritis Care & Research, 2005-2011. Arthritis Care and Research, 2011, 63, 787-787.	1.5	0
515	Excellence in Rheumatology 2012 25-28 January Madrid. International Journal of Rheumatic Diseases, 2012, 15, e17-e18.	0.9	0
516	Systemic Lupus Erythematosus, Animal Models. , 2014, , 1134-1141.		0
517	A serine/threonine phosphatase, PP2A, controls autoimmunity. Arthritis Research and Therapy, 2014, 16, A30.	1.6	0
518	T Cells and Autoimmunity. , 2015, , 85-108.		0
519	Principles of Signaling. , 2017, , 408-417.		0
520	T Cells in Autoimmune Diseases. , 2019, , 29-36.		0
521	SP0083â€¦MOLECULAR AND METABOLIC EVENTS WHICH UNDERWRITE T CELL PHENOTYPES IN AUTOIMMUNITY. , 2019, , .		0
522	201â€¦Ustekinumab targets a novel mechanism of action to treat patients with systemic lupus erythematosus. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
523	T Cells. , 2019, , 116-124.		0
524	09â€¦Reduction of interferon- $\beta$ and elevated baseline cytotoxic gene expression in the blood associate with ustekinumab response in SLE. , 2020, , .		0
525	The Clinical Spectrum of Anti-Insulin Receptor Antibodies and Autoimmune Disease. Journal of Clinical Rheumatology, 2001, 7, 361-362.	0.5	0
526	CTLA-4 expression regulation and its functions in systemic lupus erythematosus (SLE). FASEB Journal, 2008, 22, 667.9.	0.2	0
527	Pathogenesis of lupus. , 2015, , 1082-1087.		0